Short-Term Debt to Equity: knowlabs.co (KNW)

Know Labs, Inc. (KNW) price action reflects the current 0.00 metric, as the business relies on the development of sensors for non-invasive glucose monitoring, generating profit through licensing and direct sales. High profitability and a rapid influx of free cash flow are driven by proprietary radio-frequency developments. Meanwhile, multi-year FDA reviews and a robust patent portfolio create significant barriers to entry for new players in the segment.

This ratio determines the share of short-term liabilities within the equity structure, allowing for an assessment of liquidity risk and the efficiency of debt financing management. By analyzing the current level of short-term pressure on capital, an investor can evaluate the financial stability of Know Labs, Inc. (KNW) in the face of geopolitical component supply disruptions and complexities regarding international patent protection.